Encaleret is under clinical development by BridgeBio Pharma and currently in Phase III for Autosomal Dominant Hypocalcemia. According to GlobalData, Phase III drugs for Autosomal Dominant Hypocalcemia does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Encaleret LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Encaleret overview
Encaleret is under development for the treatment of autosomal dominant hypocalcemia type 1 (ADH1). The drug candidate is administered by oral route as tablet and solution. It acts by targeting calcium sensing receptor (CaSR).
BridgeBio Pharma overview
BridgeBio Pharma (BridgeBio) is a clinical-stage biotechnology company that develops novel medicines for genetic diseases. The company’s pipeline product portfolio includes precision cardiorenal drugs such as acoramidis, encaleret, BBP-711; mendelian disease drugs which include acoramidis, fosdenopterin, patidegib topical gel, low-dose infigratnib, BBP-589, BBP-551, BBP-418, BBP-681, BBP-671, among others; precision oncology drugs which include high-dose infigratinib, BBP-398, BBP-454, BBP-954. BridgeBio also carries out various phases of clinical trials such as pre-clinical, phase I, phase II studies. The company’s academic partners which include Medical University of South Carolina, University of Pittsburgh, Oregon Health, and Science University, among others. Its industry partners which include Helsinn, Alexion, Bristol Myers Squibb, among others. BridgeBio is headquartered in Palo Alto, California, the US.
For a complete picture of Encaleret’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
